Trellus Health Share Discussion Threads

[sharw] 10/6/2022 14:20

adobbing - just checked my ii a/c and still not there, today being the 8th working day since they should have been released. Googled Broadway Nominees to see if I could contact them and all I could get was Companies House who have them as a dormant company!!

I have emailed Walbrook who do Investor Relations for both EKF and TRLS.

[e-mail]

[adobbing] 01/6/2022 09:03

Just checked their website and found this -

“Restrictions in transfer of AIM Securities

There are no restrictions on the transfer of the Company’s ordinary shares except for shareholders who received distribution in specie from EKF Diagnostic Holdings plc which will expire on 28 May 2022.”

Do you think this now requires action at the company end or the ISA provider end?

I’d like to give somebody the nudge required, but unsure who!

[9degrees] 31/5/2022 12:31

same as barclays smart investor

[adobbing] 31/5/2022 08:15

My “in specie” shares still showing in my ii ISA with £0 value.

[adobbing] 27/5/2022 10:30

I will check my in specie shares on Monday, still currently showing in my ii ISA with £0 value.
At least they back pedalled on their demand that I had to love them out of the ISA, probably because they didn’t know how to do it!

[wan] 27/5/2022 10:21

Yes that's correct.

[9degrees] 27/5/2022 09:50

28 may is unlock day isn't it for in specie dividend shares ? Tomorrow
ie 365 days after admission to Aim

[brummy_git] 10/5/2022 10:03

Analyst comments wrt today's prelims.

www.linkedin.com/posts/paul-hill-a5994116_trls-trls-activity-6929715419037483009-tkEi?utm_source=linkedin_share&utm_medium=member_desktop_web

[wan] 10/5/2022 08:53

Interesting evolution/change in strategy, which should be a more scalable, robust and sustainable offering, with managements expectation to deliver a significant number of additional patients in Q4 2022.

From my perspective, whilst the evolution in strategy is welcome (and needed), it will be interesting to see how differentiated the Trellus offering is, of which the delivery of a significant number of patients across B2B and DCT, including those resulting from the advanced discussions with numerous large pharmaceutical companies and patient advocacy groups, will likely prove to be an important indicator for what lies ahead, especially as this will be for only IBD.

Furthermore, expanding into other chronic conditions that can benefit from a 'disease-agnostic' approach to assessing and building resilience and thereby improving mental health, if proven 'commercially' to demonstrate meaningful improvements in patient outcomes whilst generating significant cost savings for healthcare payers, along with the significant unmet need, could result in very high rates of growth.

Therefore, against a challenging backdrop, the next 6 months could be pivotal (one way or another).

[adobbing] 31/3/2022 13:47

Yes, I will probably look for an alternative to ii, they aren’t easy to deal with!
Although I’m struggling to see a better alternative!

[sharw] 31/3/2022 13:02

adobbing - thanks for the update. What a shambles! They are still referring to the 'A' ordinary shares that I pointed out to them 4 weeks ago have not existed since 28th May last year.

[sharw] 11/3/2022 18:17

adobbing - I have now had a reply saying that the line in my portfolio for Trellus is a dummy line to reflect those shares which I am due to receive in the future. This makes their statement to you all the more bizarre - if it is a dummy line there is nothing to be moved elsewhere!

[adobbing] 04/3/2022 20:57

@sharw

Thanks for the update.
I’d almost forgotten about them, until I got the note.
My understanding was that they would convert at some point in time, to tradable shares.
I did buy some Trellus and my original intention was to hold until the two holdings merged, then sell.
But with the fall in price I liquidated those a while back.

I’ll follow up with them next week!

[sharw] 04/3/2022 20:30

adobbing - just seen your note re ii action needed. I find this quite extraordinary - these were issued over a year ago - why has ii only just taken action - I had a share which delisted and my memory says the rule then was that you had 30 days to transfer out of an ISA. Furthermore there have been no other comments here on other brokers doing the same.

I think you should challenge this on the grounds that they are talking about Trellus Health A ordinary shares and these no longer exist, Check this -

As I read it the A ordinary shares converted to ordinary shares on 28th May last year (on AIM admission) and those shares certainly are ISA admissable unless there is some HMRC clause that says not because you are prevented from trading them until 28th May this year.

I have now told ii about this wrong description (they are in my trading a/c so I did not get the message you did) saying that if they are correctly described it will show the market value, not zero.

[brummy_git] 04/3/2022 15:47

Justin Waite & I of Vox Markets discussed Trellus health here today (starts 47:30).

www.voxmarkets.co.uk/articles/stocks-to-follow-on-vox-markets-4th-march-2022-ef5d2a0

[mikemine1] 28/2/2022 11:07

Can't be anything other than very good news. Sales mean revenue even if it will probably be slow to build as it is on a case by case flow. The more important point is that TRLS has a commercial service ready to go and it will now be able to prove the concept in real live paying patients.

[brummy_git] 28/2/2022 08:09

New BTC healthcare service launched by Trellus Health.

A pioneer providing a ‘1st-of-its-kind’ IBD resilience/AI enabled chronic disease management platform

All the news & commentary here.

www.linkedin.com/posts/paul-hill-a5994116_trls-nhs-trls-activity-6903972946566868992-GQDm

[albert arthur] 28/2/2022 08:01

Added some this am.

[adobbing] 23/2/2022 15:31

Just got a note on my ii account relating to the shares issued by EKF;

Stock
TRELLUS HEALTH A ORDINARY
Event Type
Confirmation
Description
ISA-Ineligible Holding

Name of stock: Trellus Health
Date by which you need to transfer, or request withdrawal: 9th March 2022

Your Trellus Health A ordinary shares are not deemed to be ISA-eligible under HMRC rules. You therefore have until 9th March 2022 to request that we move them from your ISA account into your ii Trading account if you have one. In order to move the shares please select “Cash & Transfers” from your account page, then “Transfer in”, and “Account to Account Transfer”. A new page will open where you will be able to instruct us to transfer the shares. Alternatively, you may wish to withdraw the shares into certificated form which will be registered in your own name and posted to you; please contact us by phone if that is the case.

If you take no action before 9th March 2022, we will endeavour to remove the shares from your ISA. This may involve transferring the shares into your Trading account if you have one, opening a Trading account on your behalf and transferring the shares into that account, or withdrawing the shares and re-registering them into your own name. Which of these options applies will be determined by us at the time in our capacity as the ISA Manager.

Withdrawals are not possible for Junior ISA Accounts so if you hold these shares in a Junior ISA they will remain on the account.


Anybody had similar and if so what are you doing?

[hybrasil] 21/2/2022 11:30

All the positive talk has the share at 33p as opposed to the flotation price last year of .40p

[brummy_git] 03/2/2022 05:24

Paul Jourdan of Amati Global talks positively briefly about Trellus Health here (starts 44:00)
www.youtube.com/watch?v=0nJJIpsI9Uo

[brummy_git] 22/1/2022 04:00

TRLS (starts 20:50) discussed by Paul Hill & Justin Waite of Vox markets here

www.youtube.com/watch?v=gA_6tDwJA5k

[mikemine1] 17/1/2022 18:54

Those improvement figures are nothing short of astounding and any clinical trial with those numbers would be deemed a significant success.

The report may not have set the Market alight but the revenues that should follow will, as clinicians take up what TRLS is offering.

[brummy_git] 17/1/2022 09:30

More positive clinical data supporting the use of Trellus Health's proprietary chronic disease management platform.

All the news & comment here.

www.linkedin.com/posts/paul-hill-a5994116_trls-nhs-activity-6888773505538641920-CUFh